A professional look at how gastroenterology HCPs balance colonoscopy, non-invasive screening, early-cancer sensitivity, patient risk, follow-up capacity, and emerging biomarker-based options in colorectal cancer screening.
Audience: Gastroenterology HCPs
Countries: 4
Completion Rate: 77.1%
SGID: 9007114
-Hero findings
– Quick Read — Key Findings
The first screening decision is often whether the patient still belongs in an average-risk pathway at all.
Family history is the factor most often changing screening approach at 35.7%, ahead of hereditary cancer syndrome (26.2%), age and eligibility (23.8%) and previous advanced adenoma (14.3%). That matters because screening and surveillance are not interchangeable: a patient with a strong family history, hereditary syndrome, prior advanced neoplasia or symptoms may need a different interval, test or diagnostic pathway from an average-risk adult.
For average-risk adults, the survey shows a clear procedural preference even as non-invasive options continue to expand.
Colonoscopy is favored by 78.6%, against FIT at 14.3% and stool DNA-FIT at 7.1%, a strong respondent preference that should not be read as a universal guideline hierarchy across countries. Guidelines differ by health system: the American College of Gastroenterology identifies colonoscopy and FIT as primary methods, while the European Society of Gastrointestinal Endoscopy supports organized FIT-based programs in many average-risk populations, with endoscopy capacity and local design shaping the pathway.
The respondents place the greatest weight on what a test can detect, particularly at an early stage.
Sensitivity for early CRC is the test characteristic that most drives choice, selected by 57.1%, with sensitivity for advanced neoplasia at 33.3% and specificity and adherence at 4.8% each. That creates a tension for non-invasive screening: a test may cut preparation or procedural burden, but clinicians still need confidence the trade-off in detection performance suits the patient and the intended use.
Non-invasive testing raises two different concerns: whether early cancer may be missed and what happens when an abnormal result sends a patient onward.
The confidence gap is two-sided: limited early-CRC sensitivity leads at 35.7%, closely followed by false positives at 31.0%, with insufficient prospective validation (21.4%) and uncertain clinical outcomes (11.9%) behind. The open comments reinforce both sides, some describe positive stool tests that rightly led to colonoscopy and detected cancer or adenoma, others describe unnecessary colonoscopies after false positives or delayed diagnosis after a negative result.
The strongest consensus in the survey appears after the screening test has already produced an abnormal result.
Diagnostic colonoscopy is the preferred next step for 88.1% of respondents, with only 9.5% repeating the non-invasive test and 2.4% choosing an alternative, confirming the positive test as a handoff rather than an endpoint. That aligns with current pathways: the USPSTF states positive stool-based results require colonoscopy for the screening benefit to be achieved, and ACG guidance similarly describes non-invasive screening as a two-step pathway when the initial test is positive.
Innovation may expand the front end of CRC screening, but respondents still see constraints in what happens after a test is offered.
Follow-up colonoscopy capacity is the leading implementation barrier at 35.9%, ahead of insufficient clinical evidence (28.2%) and limited test availability (25.6%); looking ahead, 38.5% pick highly sensitive blood-based tests as the development most likely to transform screening within 3 to 5 years, and 30.8% multimodal biomarker testing. Blood-based screening is no longer theoretical: the FDA approved a blood-based CRC screening test in 2024 for selected average-risk adults, while specifying that positive results require colonoscopy and that it does not replace diagnostic or high-risk surveillance colonoscopy.
The survey does not describe a simple contest between colonoscopy and non-invasive testing. It describes a pathway in which risk determines who belongs in routine screening, test performance shapes clinician confidence, and colonoscopy remains essential when screening is positive or the patient is no longer average risk.
That is where the implementation challenge becomes visible: if non-invasive testing expands without adequate diagnostic capacity, stronger evidence, clear guideline positioning and reliable follow-up, screening can become easier to start without becoming easier to complete.
The future may bring more blood-based and multimodal biomarker options, so the clinical question is not only whether a new test can detect colorectal cancer, but where it fits, which patients it serves, what a positive or negative result means next, and whether the system can complete the pathway safely.
You have read the summary
Discover the complete research behind these insights, or become part of future studies with MDForLives.
Direct answers to common professional questions about colonoscopy, non-invasive screening, risk, blood-based testing, and diagnostic follow-up.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
